Jaap V. L.
- Country
- The Netherlands
- Department
- Rheumatology & Clin. Immunology
Research Overview
- Evaluation of Filgotinib on Quality of Life, Disease Activity, and Safety in Refractory Behcet's Disease, Idiopathic Inflammatory Myopathies, and IgG4-Related Disease
- Comparative Efficacy of Autologous Hematopoietic Stem Cell Transplantation Versus Immunosuppressive Therapy in Early Diffuse Cutaneous Systemic Sclerosis
- Evaluation of Filgotinib Efficacy and Safety in Refractory Idiopathic Inflammatory Myopathies, Behçet's Disease, and IgG4-Related Disease
Data & Insights
Has run more than one trial at 4 of 11 partner sites.
Specializations
Inflammatory Disorders
The investigator specializes in treating rare immune-mediated inflammatory diseases, with particular focus on Behcet's disease and IgG4-related disease.
- Behcet's Disease Management
- IgG4-Related Disease Treatment
- Inflammatory Response Regulation
Their research explores innovative therapeutic approaches for managing these complex inflammatory conditions.
Myopathy Research
The investigator focuses on understanding and treating idiopathic inflammatory myopathies, exploring targeted therapeutic interventions for muscle inflammation.
- Inflammatory Muscle Disorders
- Refractory Disease Management
- Novel Treatment Approaches
Their work addresses complex cases of inflammatory muscle conditions requiring specialized therapeutic strategies.
Systemic Sclerosis
The investigator conducts research in diffuse cutaneous systemic sclerosis, particularly focusing on stem cell transplantation approaches and treatment optimization.
- Advanced Therapeutic Strategies
- Organ Failure Prevention
- Immunosuppressive Therapy
Their research evaluates treatment strategies for early intervention in systemic sclerosis.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.